- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04856085
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (MARCH)
September 22, 2023 updated by: Vir Biotechnology, Inc.
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Subjects may be enrolled into cohorts 1a, 2a, 3a, 4a, 5a, 6a, 1b, and 2b in a non-randomized manner.
Subjects may be enrolled in cohorts 7a, 8a, 1c, and 2c and will be randomized.
Study Type
Interventional
Enrollment (Estimated)
415
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Inquiry
- Phone Number: 415-654-5281
- Email: clinicaltrials@vir.bio
Study Locations
-
-
-
Toronto, Canada, 2C4
- Recruiting
- Investigative Site
-
Toronto, Canada, 3M1
- Recruiting
- Investigative Site
-
Vancouver, Canada, 2C7
- Recruiting
- Investigative Site
-
-
-
-
-
Frankfurt, Germany, 60590
- Recruiting
- Investigative Site
-
Hannover, Germany, 30625
- Recruiting
- Investigative Site
-
Mannheim, Germany, 68167
- Recruiting
- Investigative Site
-
Ulm, Germany, 89081
- Recruiting
- Investigative Site
-
-
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Investigative Site
-
-
Shatin
-
Hong Kong, Shatin, Hong Kong
- Recruiting
- Investigative Site
-
-
Tai Po
-
Hong Kong, Tai Po, Hong Kong
- Recruiting
- Investigative Site
-
-
-
-
-
Busan, Korea, Republic of, 49421
- Recruiting
- Investigative Site
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Investigative Site
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Investigative Site
-
Yangsan, Korea, Republic of, 50612
- Recruiting
- Investigative Site
-
-
-
-
-
Batu Caves, Malaysia, 68100
- Recruiting
- Investigative Site
-
Kajang, Malaysia, 43000
- Recruiting
- Investigative Site
-
Kuala Lumpur, Malaysia, 59100
- Recruiting
- Investigative Site
-
-
-
-
-
Chisinau, Moldova, Republic of, MD 2025
- Recruiting
- Investigative Site
-
-
-
-
-
Auckland, New Zealand, 1010
- Recruiting
- Investigative Site
-
Auckland, New Zealand, 2025
- Recruiting
- Investigative Site
-
Hamilton, New Zealand, 3204
- Recruiting
- Investigative Site
-
Tauranga, New Zealand, 3110
- Recruiting
- Investigative Site
-
Wellington, New Zealand, 6021
- Recruiting
- Investigative Site
-
-
-
-
-
Bucharest, Romania, 021105
- Recruiting
- Investigative Site
-
-
-
-
-
Chiayi City, Taiwan, 60041
- Recruiting
- Investigative Site
-
Kaohsiung City, Taiwan, 80756
- Recruiting
- Investigative Site
-
Kaohsiung City, Taiwan, 83301
- Recruiting
- Investigative Site
-
Taichung City, Taiwan, 40705
- Recruiting
- Investigative Site
-
Taipei City, Taiwan, 100
- Recruiting
- Investigative Site
-
Taoyuan City, Taiwan, 33305
- Recruiting
- Investigative Site
-
-
-
-
-
Kyiv, Ukraine, 01135
- Recruiting
- Investigative Site
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- Recruiting
- Investigative Site
-
London, United Kingdom, SE5 9RS
- Recruiting
- Investigative Site
-
London, United Kingdom, E11FR
- Recruiting
- Investigative Site
-
Manchester, United Kingdom, M8 5RB
- Recruiting
- Investigative Site
-
-
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- Investigative Site
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Investigative Site
-
Orlando, Florida, United States, 32803
- Recruiting
- Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Recruiting
- Investigative Site
-
-
New Jersey
-
Hillsborough, New Jersey, United States, 08844
- Recruiting
- Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female ages 18 - <66 years
- Chronic HBV infection for >/= 6 months
- On NRTI therapy for >/= 2 months at the time of screening
Exclusion Criteria:
- Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
- Significant fibrosis or cirrhosis
- History or evidence of drug or alcohol abuse
- History of chronic liver disease from any cause other than chronic HBV infection
- History of hepatic decompensation
- History of anaphylaxis
- History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434
- History of immune complex disease
- History of known contraindication to any interferon product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1a (VIR-2218 + VIR-3434)
Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 2a (VIR-2218 + VIR-3434)
Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 3a (VIR-2218 + VIR-3434)
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 4a (VIR-2218 + VIR-3434)
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 5a (VIR-2218 + VIR-3434)
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 6a (VIR-2218 + VIR-3434)
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 7a (VIR-2218 + VIR-3434)
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 8a (VIR-2218 + VIR-3434)
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 1b (VIR-3434)
Participants will receive multiple doses of VIR-3434 for 44 weeks
|
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 2b (VIR-3434)
Participants will receive multiple doses of VIR-3434 for 20 weeks
|
VIR-3434 given by subcutaneous injection
|
Experimental: Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)
Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
PEG-IFNα given by subcutaneous injection
|
Experimental: Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)
Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks
|
VIR-2218 given by subcutaneous injection
VIR-3434 given by subcutaneous injection
PEG-IFNα given by subcutaneous injection
|
Experimental: Cohort 1d (VIR-2218 + PEG-IFNα)
Participants will receive multiple doses of VIR-2218 + PEG-IFNα for 48 weeks
|
VIR-2218 given by subcutaneous injection
PEG-IFNα given by subcutaneous injection
|
Experimental: Cohort 2d (VIR-3434 + PEG-IFNα)
Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks
|
VIR-3434 given by subcutaneous injection
PEG-IFNα given by subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants with treatment-emergent adverse events (TEAEs)
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
Proportion of participants with serious adverse events (SAEs)
Time Frame: Up to 116 weeks
|
Up to 116 weeks
|
Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment
Time Frame: Up to 72 weeks
|
Up to 72 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute serum HBsAg and change from baseline across all timepoints in the study
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Nadir and maximum reduction of serum HBsAg from baseline
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs)
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Cmax
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Clast
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Tmax
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Tlast
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
AUCinf
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
AUClast
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
%AUCexp
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
t1/2
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
λz
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Vz/F
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
CL/F
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation
Time Frame: Up to 60 weeks
|
Up to 60 weeks
|
|
Proportion of participants meeting criteria for NRTI retreatment
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment
Time Frame: Up to 48 weeks
|
Up to 48 weeks
|
|
Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment
Time Frame: Up to 72 weeks
|
48 weeks treatment + 24 weeks post-end of treatment
|
Up to 72 weeks
|
Proportion of participants with anti-HBs seroconversion
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Time to achieve nadir of serum HBsAg
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
|
Time to achieve serum HBsAg loss
Time Frame: Up to 110 weeks
|
Up to 110 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 11, 2021
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
April 21, 2021
First Submitted That Met QC Criteria
April 21, 2021
First Posted (Actual)
April 22, 2021
Study Record Updates
Last Update Posted (Actual)
September 26, 2023
Last Update Submitted That Met QC Criteria
September 22, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Chronic Disease
- Hepatitis B
- Hepatitis
- Hepatitis A
- Virus Diseases
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Herpesviridae Infections
Other Study ID Numbers
- VIR-2218-1006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
Clinical Trials on VIR-2218
-
Vir Biotechnology, Inc.RecruitingHepatitis D, ChronicNew Zealand, United Kingdom, France, Moldova, Republic of, Romania, Bulgaria, Germany, Italy, Netherlands
-
Vir Biotechnology, Inc.RecruitingA Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218Renal ImpairmentUnited States
-
Vir Biotechnology, Inc.RecruitingCirrhosis | Hepatic ImpairmentUnited States
-
Brii Biosciences LimitedAlnylam Pharmaceuticals; Vir Biotechnology, Inc.Completed
-
Vir Biotechnology, Inc.Active, not recruitingHepatitis B, ChronicHong Kong, Korea, Republic of, United Kingdom, France, Moldova, Republic of, Romania
-
Vir Biotechnology, Inc.Alnylam PharmaceuticalsCompletedChronic Hepatitis BAustralia, Hong Kong, Korea, Republic of, New Zealand, Thailand
-
Brii Biosciences LimitedVBI Vaccines Inc.; Vir Biotechnology, Inc.CompletedHepatitis B, ChronicAustralia, China, Korea, Republic of, New Zealand, Singapore, Thailand
-
National Institute of Diabetes and Digestive and...Not yet recruiting
-
Vir Biotechnology, Inc.Terminated